Henan Lingrui Pharmaceutical Co Ltd
SSE:600285
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Henan Lingrui Pharmaceutical Co Ltd
Change in Working Capital
Henan Lingrui Pharmaceutical Co Ltd
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Henan Lingrui Pharmaceutical Co Ltd
SSE:600285
|
Change in Working Capital
-¥2.2B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-20%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Change in Working Capital
-¥382.8m
|
CAGR 3-Years
15%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Change in Working Capital
-¥17.8B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-12%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Change in Working Capital
-¥6.6B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-8%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Change in Working Capital
-¥2.3B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-12%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Change in Working Capital
-¥1.5B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
Henan Lingrui Pharmaceutical Co Ltd
Glance View
Nestled in the heart of China's Henan province, Henan Lingrui Pharmaceutical Co Ltd has quietly crafted a legacy in the pharmaceutical sector, blending traditional Chinese medicine with modern medical practices. Founded in an environment rich in natural resources, the company takes pride in its extensive portfolio that includes a broad range of pharmaceutical products such as tablets, injections, ointments, and Chinese patent medicines. The company's approach is an intricate dance between ancient wisdom and contemporary science, where herbal remedies are often synthesized with cutting-edge pharmaceutical manufacturing processes. Priding itself on research and development, Lingrui regularly collaborates with esteemed medical institutions, ensuring that its offerings remain both innovative and deeply rooted in traditional therapeutic principles. The financial heartbeat of Henan Lingrui is sustained through a strategic balance of domestic sales and international exports, capitalizing on the rising global demand for natural and alternative medicines. As the company expands its footprint, it continues to harness its robust supply chain and distribution channels to seamlessly deliver its products to hospitals, pharmacies, and health institutions across various regions. Indeed, the harmonious blend of traditional and modern methodologies not only defines Lingrui's operations but also shapes its revenue streams. By adhering to stringent quality standards and fostering partnerships, Henan Lingrui Pharmaceutical not only thrives in its local market but also competes in diverse international arenas, leveraging its unique product offerings as a cornerstone for financial growth.
See Also
What is Henan Lingrui Pharmaceutical Co Ltd's Change in Working Capital?
Change in Working Capital
-2.2B
CNY
Based on the financial report for Sep 30, 2025, Henan Lingrui Pharmaceutical Co Ltd's Change in Working Capital amounts to -2.2B CNY.
What is Henan Lingrui Pharmaceutical Co Ltd's Change in Working Capital growth rate?
Change in Working Capital CAGR 10Y
-20%
Over the last year, the Change in Working Capital growth was -27%. The average annual Change in Working Capital growth rates for Henan Lingrui Pharmaceutical Co Ltd have been -19% over the past three years , -13% over the past five years , and -20% over the past ten years .